China’s State FDA Says Merck Recalled Meningitis Vaccine (China)
This article was originally published in PharmAsia News
Executive Summary
China's State FDA says U.S. drug maker Merck has recalled its Pedvaxhib (haemophilus b) conjugate vaccine for preventing meningitis and other diseases because of a sterilization problem in one of its U.S. factories. Merck said it recalled Pedvaxhib and similar Comvax vaccines after it discovered the sterilization problem in its Pennsylvania factory. No cases of children receiving Hib for preventing meningitis, pneumonia and other infections were reported, although infections usually take at least a week to develop. Hib is combined with a hepatitis B vaccine to prevent the other diseases. (Click here for more
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.